Pharmaceuticals & Therapeutics

Millions suffer from osteoporosis, but many refuse injections. Now, a biotech company's oral pill aims to bridge a massive treatment gap. Here's how.

Tenvie Therapeutics begins human trials for TNV108, a drug that targets the root cause of nerve decay, offering a potential disease-modifying breakthrough.

Upcoming Phase 1 data for ABCL635 could validate a novel antibody approach for hot flashes, challenging the market and offering new hope for millions.

TruHeight Vitamins lands in Target stores nationwide, but a federal settlement over its growth claims casts a shadow on the major retail expansion.

Biogen consolidates worldwide rights for its promising immunology drug felzartamab, acquiring China rights from TJ Biopharma in a strategic $850M deal.

Blue Cross Blue Shield of Michigan postpones a major payment change after intense, coordinated pressure from osteopathic physician groups.

New data reveals a novel cancer drug shrinks brain metastases in over half of small cell lung cancer patients, offering hope where options are scarce.

Presented at AACR 2026, first-in-class antibody IMT-009 shows clinical benefit in tough cancers, potentially paving the way for a new precision therapy.

A new partnership between Wilcrest Pharma and healthcare giant Premier, Inc. aims to streamline hazardous drug compounding for thousands of U.S. hospitals.

Dr. Jennifer Shuford, a crisis-tested leader from Texas, is named CDC Deputy Director, a move experts hope will stabilize the beleaguered agency.

Biotech veteran Habib Dable, who led Acceleron to an $11.5B Merck sale, joins Tyra Biosciences' board, signaling a major push toward commercialization.

With $36M secured, Orthogon Therapeutics is advancing a first-in-class oral drug for BK virus, offering a new lifeline for transplant patients.

Investors eye Darling's Q1 results on April 30 for a rebound in renewable fuel profits and continued strength in its core circular economy segments.

For over a decade, Wake Radiology has backed the Komen Race for the Cure, funding research and expanding access to life-saving breast cancer screenings.

An FDA-approved system lets surgeons see residual cancer in real-time during lumpectomies, offering new hope for avoiding the dreaded second surgery.

GC Biopharma's new data on ALYGLO's purity profile could set a new standard for IVIG therapies, impacting patient safety in a rapidly growing market.

With a massively oversubscribed €600M hybrid note offering, plant-based leader Roquette secures major funding and a huge vote of investor confidence.

Despite major cost cuts and growth in key divisions, DSS, Inc. struggles to convince Wall Street. Can a biotech spin-off finally unlock its true value?

With key advisory appointments, NeuraClick aims to overcome long-standing hurdles in peptide drug development for complex brain and metabolic disorders.

With 62 profitable quarters and a major new acquisition, BioSyent prepares to pitch its proven growth strategy to top healthcare investors in Toronto.